PTH Predicts the in-Hospital MACE After Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction

References

• Samsky MD, Morrow DA, Proudfoot AG, Hochman JS, Thiele H, Rao SV. Cardiogenic shock after acute myocardial infarction: a review. JAMA. 2021;326(18):1840–1850.
   PubMed Web of Science ®Google Scholar
• Zhang XF, Hu DY, Ding RJ, Wang HC, Yan LX. Status and trend of cardio-cerebral-vascular diseases mortality in China: data from national disease surveillance system between 2004 and 2008. Zhonghua xin xue guan bing za zhi. 2012;40(3):179–187.
   PubMedGoogle Scholar
• Li J, Li X, Wang Q, et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet. 2015;385(9966):441–451.
   PubMed Web of Science ®Google Scholar
• Flores-Blanco PJ, López-Cuenca Á, Januzzi JL, et al. Comparison of Risk Prediction With the CKD-EPI and MDRD Equations in Non-ST-Segment Elevation Acute Coronary Syndrome. Clin Cardiol. 2016;39(9):507–515.
   PubMed Web of Science ®Google Scholar
• Hadjadj S, Coisne D, Mauco G, et al. Prognostic value of admission plasma glucose and HbA in acute myocardial infarction. Diabet Med. 2004;21(4):305–310.
   PubMed Web of Science ®Google Scholar
• Shitara J, Ogita M, Wada H, et al. Clinical impact of high-sensitivity C-reactive protein during follow-up on long-term adverse clinical outcomes in patients with coronary artery disease treated with percutaneous coronary intervention. J Cardiol. 2019;73(1):45–50.
   PubMed Web of Science ®Google Scholar
• Grønhøj MH, Gerke O, Mickley H, et al. Associations between calcium-phosphate metabolism and coronary artery calcification; a cross sectional study of a middle-aged general population. Atherosclerosis. 2016;251:101–108.
   PubMed Web of Science ®Google Scholar
• Kestenbaum B, Katz R, de Boer I, et al. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol. 2011;58(14):1433–1441.
   PubMed Web of Science ®Google Scholar
• Anderson JL, Vanwoerkom RC, Horne BD, et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am Heart J. 2011;162(2):331–339.e332.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Landaluce C, Aceña Á, Pello A, et al. Parathormone levels add prognostic ability to N-terminal pro-brain natriuretic peptide in stable coronary patients. ESC Heart Failure. 2021;8(4):2713–2722.
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177.
   PubMed Web of Science ®Google Scholar
• Kolh P, Windecker S. ESC/EACTS myocardial revascularization guidelines 2014. Eur Heart J. 2014;35(46):3235–3236.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031–2037.
   PubMed Web of Science ®Google Scholar
• Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967;20(4):457–464.
   PubMed Web of Science ®Google Scholar
• Kozuch M, Kralisz P, Korecki J, et al. Early and long-term prognosis of patients with coronary artery disease treated with percutaneous coronary interventions in 2005. Experience of single large-volume PCI center. Adv Med Sci. 2011;56(2):222–230.
   PubMed Web of Science ®Google Scholar
• Lin MJ, Yang WC, Chen CY, et al. Hypertension and chronic kidney disease affect long-term outcomes in patients with stable coronary artery disease receiving percutaneous coronary intervention. Sci Rep. 2018;8(1):17673.
   PubMedGoogle Scholar
• Zhang L, Xu C, Liu J, et al. Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study. Cardiovasc Diabetol. 2019;18(1):52.
   PubMedGoogle Scholar
• Sheng J, Liu N, He F, Cheng C, Shen S, Sun Y. Changes in the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios before and after percutaneous coronary intervention and their impact on the prognosis of patients with acute coronary syndrome. Clinics. 2021;76:e2580.
   PubMed Web of Science ®Google Scholar
• Ma Q, Ma Y, Wang X, et al. A radiomic nomogram for prediction of major adverse cardiac events in ST-segment elevation myocardial infarction. Eur Radiol. 2021;31(2):1140–1150.
   PubMed Web of Science ®Google Scholar
• Gao N, Qi X, Dang Y, et al. Establishment and validation of a risk model for prediction of in-hospital mortality in patients with acute ST-elevation myocardial infarction after primary PCI. BMC Cardiovasc Disord. 2020;20(1):513.
   PubMed Web of Science ®Google Scholar
• Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromsø Study. Eur j Cardiovascular Prevention Rehabilitation. 2004;11(1):69–74.
   PubMedGoogle Scholar
• Sugimoto T, Tanigawa T, Onishi K, et al. Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart. 2009;95(5):395–398.
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Jensen TS, Bang U, Jensen G, Køber L, Jensen JE. Parathyroid hormone and vitamin D--markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail. 2011;13(6):626–632.
   PubMed Web of Science ®Google Scholar
• Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115(2):173–179.
   PubMed Web of Science ®Google Scholar
• Royakkers AA, Korevaar JC, van Suijlen JD, et al. Serum and urine cystatin C are poor biomarkers for acute kidney injury and renal replacement therapy. Intensive Care Med. 2011;37(3):493–501.
   PubMed Web of Science ®Google Scholar
• Keller T, Messow CM, Lubos E, et al. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J. 2009;30(3):314–320.
   PubMed Web of Science ®Google Scholar
• Dupont M, Wu Y, Hazen SL, Tang WH. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ Heart Fail. 2012;5(5):602–609.
   PubMed Web of Science ®Google Scholar
• Malmgren L, McGuigan FE, Christensson A, Akesson KE. Longitudinal Changes in Kidney Function Estimated from Cystatin C and Its Association with Mortality in Elderly Women. Nephron. 2020;144(6):290–298.
   PubMed Web of Science ®Google Scholar
• Barrett TD, Hennan JK, Marks RM, Lucchesi BR. C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion. J Pharmacol Exp Ther. 2002;303(3):1007–1013.
   PubMed Web of Science ®Google Scholar
• Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190(12):1733–1740.
   PubMed Web of Science ®Google Scholar
• Tong DC, Whitbourn R, MacIsaac A, et al. High-Sensitivity C-Reactive Protein Is a Predictor of Coronary Microvascular Dysfunction in Patients with Ischemic Heart Disease. Front Cardiovascular Med. 2017;4:81.
   PubMed Web of Science ®Google Scholar
• Mazhar F, Tariq SR, Bashir F. Age- and gender-based studies of trace metal levels and various enzymes associated with myocardial infarction. Biol Trace Elem Res. 2011;140(2):139–150.
   PubMed Web of Science ®Google Scholar
• Chareonthaitawee P, Christian TF, Hirose K, Gibbons RJ, Rumberger JA. Relation of initial infarct size to extent of left ventricular remodeling in the year after acute myocardial infarction. J Am Coll Cardiol. 1995;25(3):567–573.
   PubMed Web of Science ®Google Scholar
• van der Horst IC, Nijsten MW, Vogelzang M, Zijlstra F. Persistent hyperglycemia is an independent predictor of outcome in acute myocardial infarction. Cardiovasc Diabetol. 2007;6:2.
   PubMed Web of Science ®Google Scholar
• Shiraishi J, Kohno Y, Nakamura T, et al. Predictors of in-hospital outcomes after primary percutaneous coronary intervention for acute myocardial infarction in patients with a high Killip class. Internal Med. 2014;53(9):933–939.
   PubMed Web of Science ®Google Scholar
• Zabojszcz M, Januszek R, Siudak Z, et al. Association between the mortality rate and operator volume in patients undergoing emergency or elective percutaneous coronary interventions. Kardiol Pol. 2020;78(2):138–146.
   PubMed Web of Science ®Google Scholar
• Tokarek T, Dziewierz A, Plens K, et al. Percutaneous coronary intervention during on- and off-hours in patients with ST-segment elevation myocardial infarction. Hellenic j Cardiol. 2021;62(3):212–218.
   PubMed Web of Science ®Google Scholar